Get the Stockscreener App
1.03
0.98%
0.01
Pre-market:
1.03
Humacyte Inc stock is traded at $1.03, with a volume of 3.83M.
It is up +0.98% in the last 24 hours and down -3.74% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.02
Open:
$1.03
24h Volume:
3.83M
Relative Volume:
0.80
Market Cap:
$198.79M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-0.9626
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+0.98%
1M Performance:
-3.74%
6M Performance:
-59.29%
1Y Performance:
-77.16%
1-Day Range:
$0.97
$1.035
1-Week Range:
$0.9581
$1.15
52-Week Range:
$0.91
$4.85
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.03 | 196.86M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Dividend Watch: Does ASTE have strong fundamentalsJuly 2025 Gainers & Community Verified Trade Signals - baoquankhu1.vn
Pharma News: What are the analyst revisions for Air T IncIs Humacyte Inc stock a good investment in YEAR2025 Short Interest & Community Verified Swing Trade Signals - baoquankhu1.vn
Smart Money: What is the target price for Humacyte Inc Equity Warrant stockRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Rate Cut: What is the target price for Humacyte Inc Equity Warrant stockNew Guidance & Daily Growth Stock Tips - baoquankhu1.vn
Aug Swings: Whats the fair value of Humacyte Inc Equity Warrant stockJuly 2025 Volume & Daily Chart Pattern Signals - baoquankhu1.vn
Stop Loss: Will Humacyte Inc benefit from rising consumer demandRisk Management & Technical Confirmation Trade Alerts - baoquankhu1.vn
Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Volatility Watch: What are Humacyte Incs technical support levelsTrade Analysis Summary & Community Supported Trade Ideas - baoquankhu1.vn
Humacyte (NASDAQ:HUMA) Given New $10.00 Price Target at Benchmark - MarketBeat
Benchmark lowers Humacyte stock price target to $10 on Israel filing plans - Investing.com India
Humacyte Stock (HUMA) Opinions on Recent Price Surge - Quiver Quantitative
Whale Trades: Whats the fair value of Humacyte Inc stock2025 Price Momentum & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Humacyte, Inc. (HUMA) Stock Analysis: Exploring a Potential 614% Upside in the Biotech Sector - DirectorsTalk Interviews
Published on: 2026-01-15 08:53:32 - baoquankhu1.vn
Analyst Upgrade: Can Humacyte Inc. stock maintain growth trajectoryTrade Signal Summary & Weekly Momentum Picks - Bộ Nội Vụ
CEO Moves: What catalysts could drive Humacyte Inc. stock higherPortfolio Risk Report & Fast Gain Stock Tips - Bộ Nội Vụ
Humacyte, Inc. (NASDAQ:HUMA): Are Analysts Optimistic? - Yahoo Finance
Quarterly Risk: Does Humacyte Inc Equity Warrant stock benefit from AI growthPortfolio Return Report & Verified Swing Trading Watchlists - baoquankhu1.vn
While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most - simplywall.st
Wall Street analysts see Humacyte, Inc. (HUMA) as a buy: Should you invest? - MSN
Is Humacyte Inc. Equity Warrant stock undervalued vs historical averagesTrail vs Road Selection & quick comparison of popular models - ulpravda.ru
How buybacks impact Humacyte Inc. Equity Warrant stock valueJuly 2025 Gainers & Entry Point Confirmation Alerts - ulpravda.ru
Will Humacyte Inc. Equity Warrant stock gain from lower inflationPortfolio Gains Report & Fast Gaining Stock Reports - ulpravda.ru
Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Potential 571.55% Upside in the Biotech Sector - DirectorsTalk Interviews
Is Humacyte Inc. Equity Warrant stock a contrarian buyQuarterly Growth Report & Real-Time Volume Spike Alerts - ulpravda.ru
Will Humacyte Inc. stock recover faster than peersJuly 2025 Movers & Reliable Intraday Trade Alerts - ulpravda.ru
Can Humacyte Inc. Equity Warrant stock resist market sell offsOptions Play & Fast Gain Swing Trade Alerts - ulpravda.ru
Winners Losers: Can Humacyte Inc. stock deliver sustainable ROE2025 Sector Review & AI Enhanced Trading Alerts - ulpravda.ru
Form 8-KCurrent report - ADVFN
What sentiment indicators say about Humacyte Inc. stockMarket Sentiment Report & Weekly High Return Stock Opportunities - ulpravda.ru
Can Humacyte Inc. stock sustain revenue growthJuly 2025 Volume & Verified Chart Pattern Trade Signals - ulpravda.ru
How strong is Humacyte Inc. Equity Warrant stock revenue growthMarket Performance Report & Precise Buy Zone Identification - ulpravda.ru
Can Humacyte Inc. stock deliver sustainable ROEQuarterly Market Summary & AI Driven Stock Reports - ulpravda.ru
Today's Analyst Ratings: Humacyte (HUMA) Maintains "Buy" Rating - GuruFocus
Humacyte enters sales agreement with TD Securities - MSN
Preventable surgery complications can drive hospital charges toward $600K - Stock Titan
Patterns Watch: Can Humacyte Inc stock deliver sustainable ROESwing Trade & Risk Managed Investment Signals - moha.gov.vn
Humacyte, Inc.Common Stock (NQ: HUMA - FinancialContent
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Humacyte rises on Symvess sale to military treatment facility - MSN
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel - marketscreener.com
Humacyte Inc announces planned marketing authorization application for Symvess in Israël - marketscreener.com
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte plans to seek approval for vessel product in Israel By Investing.com - Investing.com Australia
Humacyte plans to seek approval for vessel product in Israel - Investing.com
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - The Manila Times
Humacyte, Inc. (HUMA) Stock Analysis: Exploring A Potential 718% Upside In Biotechnology - DirectorsTalk Interviews
Rate Hike: Is Humacyte Inc stock attractive for income investorsDollar Strength & Daily Entry Point Trade Alerts - moha.gov.vn
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):